Skip to content
  1. Home
  2. News
  3. Ginkgo Bioworks to Become a Public Company and Expand its Leading Platform for Cell Programming

Ginkgo Bioworks to Become a Public Company and Expand its Leading Platform for Cell Programming

Deals & Cases
May 11, 2021
Vinson & Elkins Advises Certain Stockholders of Ginkgo Bioworks in Business Combination Agreement with Soaring Eagle Acquisition Corp. Background Image
Deals & Cases
May 11, 2021

Vinson & Elkins advised certain stockholders of Ginkgo Bioworks, Inc. (“Ginkgo”), including Viking Global Investors, in connection with a business combination agreement between Ginkgo, which is building the leading horizontal platform for synthetic biology, and Soaring Eagle Acquisition Corp., a publicly traded special purpose acquisition company, that will result in Ginkgo becoming a publicly-listed company.

The transaction values Ginkgo at a $15 billion pre-money equity valuation and is expected to provide up to $2.5 billion of primary proceeds. V&E also advised the stockholders in their PIPE investments in the transaction.

The V&E corporate team was led by partners John Kupiec and Ramey Layne and senior associate Stancell Haigwood. Also advising were counsel Julia Petty; partners Jason McIntosh and David Peck and associate Curt Wimberly; and partner Hill Wellford and senior associate Ryan Will.

About Vinson & Elkins
For more than a century, Vinson & Elkins has provided outstanding client service across important industries that drive the global economy. Built on a strong culture of collaboration across 11 offices worldwide, V&E lawyers are committed to excellence, offering clients decades of legal experience in handling transactions, investments, projects and disputes across the globe. Learn more by visiting www.velaw.com or follow us on Twitter @VinsonandElkins or connect with us on LinkedIn.

For more information, please speak with our media contacts.

Key Contacts